Liquidia (NASDAQ:LQDA) Stock: Insider Rajeev Saggar Sells 9,218 Shares

Liquidia Corporation (NASDAQ:LQDA) insider Rajeev Saggar sold 9,218 shares of Liquidia stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $28.48, for a total value of $262,528.64. Following the completion of the transaction, the insider owned 126,368 shares of the company’s stock, valued at approximately $3,598,960.64. The trade was a 6.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Rajeev Saggar also recently made the following trade(s):

• On Monday, August 17th, Rajeev Saggar sold 29,534 shares of Liquidia stock. The shares were sold at an average price of $76.84, for a total value of $2,269,392.56.
• On Wednesday, August 19th, Rajeev Saggar sold 50,000 shares of Liquidia stock. The stock was sold at an average price of $74.06, for a total value of $3,703,000.00.

Liquidia Stock Up 26.6%

Shares of Liquidia stock opened at $33.94 on Thursday. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63. The business’s 50 day simple moving average is $62.30 and its 200-day simple moving average is $61.74. The stock has a market capitalization of $3.04 billion, a price-to-earnings ratio of 24.77 and a beta of 0.61. Liquidia Corporation has a twelve month low of $21.94 and a twelve month high of $93.61.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The company had revenue of $171.68 million during the quarter, compared to the consensus estimate of $168.48 million. During the same period last year, the business posted ($0.49) EPS. The company’s revenue for the quarter was up 1842.1% on a year-over-year basis. Equities research analysts forecast that Liquidia Corporation will post 2.05 earnings per share for the current year.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: The settlement allows Liquidia to continue commercializing YUTREPIA for pulmonary arterial hypertension (PAH) without interruption, removing a major source of legal and commercial uncertainty. Liquidia settlement announcement
• Positive Sentiment: Preliminary third-quarter YUTREPIA sales reached $222.7 million, contributing to $396.1 million in cash and equivalents. Management said it expects ongoing sales and existing cash to fund settlement obligations and clinical programs without additional financing. RTTNews settlement report
• Positive Sentiment: Analyst sentiment improved following the agreement. BTIG upgraded LQDA from “neutral” to “buy” with a $70 price target, while Lifesci Capital raised its rating to “outperform” and set a $59 target. Needham maintained “buy” but lowered its target to $58.
• Positive Sentiment: Trading activity reflected strong investor interest, with call-option volume more than doubling its average level.
• Neutral Sentiment: Liquidia agreed to pay United Therapeutics a net $380.7 million, including $175 million within 30 business days, $145.4 million in 2027 installments and $60.3 million tied to the antitrust litigation. The payments resolve the disputes but will significantly draw down cash.
• Negative Sentiment: The company will not appeal the patent ruling and is removing the PH-ILD indication from YUTREPIA’s label. It also ended promotion of Treprostinil Injection, narrowing potential revenue opportunities. Zacks settlement analysis
• Negative Sentiment: Multiple executives and insiders sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested awards. Because the sales were planned and left executives with substantial holdings, they are a limited standalone signal, but broader insider activity remains heavily weighted toward selling.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on LQDA shares. Zacks Research cut Liquidia from a “hold” rating to a “strong sell” rating in a research note on Tuesday, September 22nd. Wedbush set a $58.00 price target on shares of Liquidia in a report on Friday, October 2nd. Citigroup restated a “neutral” rating on shares of Liquidia in a research report on Thursday, October 1st. Royal Bank Of Canada set a $130.00 price target on shares of Liquidia in a research report on Friday, July 24th. Finally, Weiss Ratings raised shares of Liquidia from a “sell (d-)” rating to a “hold (c)” rating in a report on Tuesday, September 22nd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $77.31.

Institutional Investors Weigh In On Liquidia

A number of hedge funds have recently made changes to their positions in the business. Globeflex Capital L P acquired a new position in shares of Liquidia during the second quarter worth approximately $175,000. Nykredit A S bought a new position in Liquidia in the 2nd quarter worth approximately $177,000. Fluent Financial LLC acquired a new stake in Liquidia in the 2nd quarter valued at approximately $287,000. WINTON GROUP Ltd acquired a new stake in Liquidia in the 2nd quarter valued at approximately $335,000. Finally, Fulcrum Equity Management acquired a new stake in Liquidia in the 2nd quarter valued at approximately $399,000. Institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).